01167 JACOBIO-B
- 1.820
- +0.020+1.11%
JACOBIO-B News
Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab
Jacobio Pharmaceuticals (HKG:1167) disclosed that their registrational phase III clinical trial of the combination therapy between novel KRAS G12C inhibitor Glecirasib (JAB-21822) and Merck's epiderma
Gacos-B (01167): A registered phase III clinical study of the KRAS G12c inhibitor Glecirasib for colorectal cancer was approved by the Chinese CDE
According to the Zhitong Finance App, Gacos-B (01167) announced that Glecirasib (JAB-21822), a KRAS G12C inhibitor independently developed by the company, and ERBITUX (cetuximab), a combination of the KRAS G12C inhibitor (anti-EGFR antibody) inhibitor ERBITUX (cetuximab) to treat KRAS G12C mutant rectal cancer has been approved for a registered phase III clinical trial in China. This registered phase III clinical trial approved in China aims to evaluate Glecirasib plus cetuximab versus positive control treatment for unresectable or metastatic KRAs
Changes in Hong Kong stocks | Gacos-B (01167) rose by more than 5%, KRAS G12C inhibitors declared for listing, outstanding efficacy and safety performance
Gacos-B (01167) rose more than 5%. The stock closed up more than 16% yesterday. As of press release, it rose 5.07% to HK$2.28, with a turnover of HK$2,031,800.
Jacobio Pharmaceuticals Submits Cancer Treatment New Drug Application to Chinese Drug Regulator; Shares Surge 22%
Jacobio Pharmaceuticals Group Co (HKG:1167) submitted a new drug application to China's National Medical Products Administration (NMPA) for its small lung cancer drug JAB-21822 based on Phase II clini
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Changes in Hong Kong stocks 丨 Gacos surged more than 30%, and the application for marketing of self-developed new drugs was officially submitted
Glonghui, May 7 | Gacos-B (1167.HK) rose sharply by more than 30%. It now reports a two-month high of HK$2.43, with a total market value of HK$1.93 billion. The new drug marketing application (NDA) for Glecirasib (JAB-21822), a KRAS G12C inhibitor developed independently by the company, has been officially submitted to the China National Drug Administration (NMPA) Drug Evaluation Center (CDE) for second-line treatment of advanced or metastatic non-small cell lung cancer patients with KRAS G12C mutations. Furthermore, Glecirasi
Gacos-B (01167): KRAS G12C inhibitor Glecirasib New Drug Application (NDA) officially submitted
Gacos-B (01167) announced that the company's self-developed KRAS G12C inhibitor Gl...
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Jacobio Pharmaceuticals Plans Auditor Change
Jacobio Pharmaceuticals Group Co (HKG:1167) has suggested that Deloitte Touche Tohmatsu be appointed as the company's new auditor during the next annual general meeting, according to a Wednesday filin
Gacos-B (01167.HK) intends to appoint Deloitte as independent auditor
On April 24, Gelonghui announced Gacos-B (01167.HK), the board of directors announced that PricewaterhouseCoopers will retire as the company's auditor. The Board of Directors has resolved to recommend the appointment of Deloitte Guan Huang Chen Fang Certified Public Accountants (“Deloitte”) as the Company's independent auditor, effective from the end of the Annual General Meeting of Shareholders.
加科思-B：2023年度報告
Featured announcements | Shunyu Optics mobile phone lens shipments increased by more than 30%; China Life Insurance's original premium revenue increased by 3.2%
Hang Seng Bank: It plans to repurchase no more than HK$3 billion of shares. The automatic share repurchase plan will run from April 10, 2024 to September 9, 2024; Shandong Gold: A wholly-owned subsidiary in Hong Kong plans to apply for a revolving loan of US$30 million from Bank of Communications (Hong Kong).
Jacobio to Share Clinical Data of Anti-Tumor Drugs at US Convention
Jacobio Pharmaceuticals Group Co (HKG:1167) presented the results of two preclinical evaluations of its PARP7 inhibitor JAB-26766, and its p53 Y220C reactivator JAB-30355, at the ongoing American Asso
Gacos-B (01167.HK) Presents Preclinical Data for PARP7 Inhibitor JAB-26766 and P53 Activator JAB-30355 at 2024 AACR Conference
Gelonghui, April 9 | Gacos-B (01167.HK) announced that the company announced the pre-clinical evaluation results of the PARP7 inhibitor JAB-26766 and the p53 Y220C activator JAB-30355 in summary form at the 2024 American Association for Cancer Research (AACR) annual meeting to be held from April 5 to April 10, 2024. JAB-26766 is an effective orally bioavailable PARP7 inhibitor. It is more than 1800 times more selective for PARP7 than PARP2. JAB-26766 as a single drug
Jacobio Pharmaceuticals Narrows 2023 Loss on Lower R&D Expenses
Jacobio Pharmaceuticals (HKG:1167) narrowed its loss attributable to owners in 2023 to 359.1 million yuan, or 0.46 yuan per share, from an attributable loss of 371.9 million yuan, or 0.49 yuan per yea
Gacos releases 2023 annual results report, core projects are about to submit new drug marketing applications
BEIJING, SHANGHAI, AND BOSTON, March 29, 2024/PRNewswire/ -- Gacos Pharmaceuticals (1167.HK) released its 2023 annual results report. During the performance period, revenue was 63.5 million yuan, R&D investment was 372 million yuan, and a capital balance of 1.2 billion yuan at the end of 2023. Gacos also announced recent business developments and expected milestones. Dr. Wang Yinxiang, Chairman and CEO of Gacos Pharmaceuticals, said, “In the past year, several Gacos projects have progressed, and the SHP2 inhibitor JAB-3312 combined with Golerese has been approved to conduct phase III registered clinical trials in China.
Press Release: Jacobio Pharma Announces 2023 Annual Results
Jacobio Pharma Announces 2023 Annual Results PR Newswire BEIJING, SHANGHAI and BOSTON, March 28, 2024 BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ -- Pharma (1167.HK), a clinica
Gacos-B (01167) achieved revenue of 63.52 million yuan in 2023
Gacos-B (01167) announced results for the year ended December 31, 2023. The group recorded revenue of 6...
加科思-B：截至2023年12月31日止年度的年度業績公告
Analysis
Price Target
No Data
